NMRA trades 800.2% below Wall Street's consensus target of $4.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NMRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Neumora Therapeutics, Inc. Common Stock (NMRA) has a Wall Street consensus price target of $4.50, based on estimates from 9 covering analysts. With the stock currently trading at $0.50, this represents a potential upside of +800.2%. The company has a market capitalization of $93M.
Analyst price targets range from a low of $4.00 to a high of $5.00, representing a 22% spread in expectations. The median target of $4.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NMRA trades at a trailing P/E of -0.3x. Analysts expect EPS to grow +20.9% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $3.4B | $19.95 | $32.32 | +62.0% | Buy | 32.4x | 37 |
 INVAInnoviva, Inc. | $1.5B | $20.50 | $38.00 | +85.4% | Buy | 8.5x | 10 |
 AXSMAxsome Therapeutics, Inc. | $9.2B | $179.25 | $281.63 | +57.1% | Buy | — | 27 |
 PRAXPraxis Precision Medicines, Inc. | $8.2B | $295.51 | $603.83 | +104.3% | Buy | — | 18 |
 PTCTPTC Therapeutics, Inc. | $5.3B | $63.46 | $106.00 | +67.0% | Buy | 49.9x | 26 |
 NRXPNRx Pharmaceuticals, Inc. | $50M | $2.90 | — | — | — | — | — |
 ALTOAlto Ingredients, Inc. | $292M | $3.77 | $10.00 | +165.3% | Buy | 10.0x | 2 |
 MNMDMind Medicine (MindMed) Inc. | $3.2B | $42.79 | $20.00 | -53.3% | Buy | — | 1 |
 LLYEli Lilly and Company | $1.1T | $1142.85 | $1343.07 | +17.5% | Buy | 31.2x | 45 |
 PFEPfizer Inc. | $158.4B | $27.80 | $28.50 | +2.5% | Hold | 9.3x | 39 |
Quick answers to the most common questions about buying NMRA stock.
The consensus Wall Street price target for NMRA is $4.5, representing 800.2% upside from the current price of $0.4999. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
NMRA has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $4.5 implies 800.2% upside from current levels.
NMRA's current price is $0.4999 with a consensus target of $4.5 (800.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for NMRA, while the most conservative target is $4. The consensus of $4.5 represents the median expectation. These targets typically reflect 12-month expectations.
NMRA is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NMRA stock forecast based on 9 Wall Street analysts shows a consensus price target of $4.5, with estimates ranging from $4 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on NMRA, with a "Buy" consensus rating and $4.5 price target (800.2% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NMRA analyst price targets range from $4 to $5, a 22% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $4.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.